Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

CXC chemokine receptor 2 (CXCR2; IL8RB)

Mouse studies suggest CXCR2 antagonists could help treat cancer. In mouse models of inflammation-driven intestinal and skin tumors, knockout of Cxcr2 decreased tumorigenesis compared with normal Cxcr2 expression. In a mouse model of primary benign intestinal adenomas, a pepducin against Cxcr2 decreased tumorigenesis compared with a nontargeting pepducin. Next steps could include clinical testing of CXCR2 antagonists in cancer models.
At least six companies have CXCR2 antagonists in Phase II testing or earlier to treat pulmonary and transplant-related indications.

SciBX 5(37); doi:10.1038/scibx.2012.978
Published online Sept. 20, 2012

Patent and licensing status unavailable

Jamieson, T. et al. J. Clin. Invest.; published online Aug. 27, 2012;
doi:10.1172/JCI61067
Contact: Thomas Jamieson,
The Beatson Institute for Cancer Research, Glasgow, U.K.
e-mail:
t.jamieson@beatson.gla.ac.uk